MetseraMTSR got a positive adjustment to its Relative Strength (RS) Rating, from 88 to 93.Please watch the video at Investors ...

Shares of Metsera Inc. (MTSR) have gained 6.8% over the past four weeks to close the last trading session at $35.32, but ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin ...

Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs ...

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...

Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR stock is a hold.

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today anno ...

Metsera, Inc., a clinical-stage biopharmaceutical company focused on treating obesity and metabolic diseases, announced its first quarter 2025 financial results, highlighting significant progress ...

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for ...

Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera’s contender, MET-233i, is ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial and the potential to have longer-lasting effects than current weight loss treatments on the ...